Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588984 · ClinicalTrials.gov registry record
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
A clinical trial, sponsored by Noom.
- Not yet
- Registry status
- 2,310
- Enrollment target
NCT07588984: Clinical Trial study, sponsored by Noom.
NCT07588984 is a clinical trial that has not yet begun recruiting, run by Noom. The registered enrollment target is 2,310 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07588984 has not yet begun recruiting, sponsored by Noom.
- NOT YET RECRUITING
- Registry status
- 2,310 participants
- Enrollment target
Study Summary
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.
Primary Outcome
Change from baseline in body weight (kg/lbs) measured via connected scale.
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- BEHAVIORAL Noom Weight
- BEHAVIORAL Free Tier
- BEHAVIORAL Education-only control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,310 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2029-05 |
What is known before NCT07588984 opens enrollment
NCT07588984 is an observational study that tracks outcomes without assigning an intervention. Its 2,310 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Tirzepatide is the first listed.
NCT07588984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07588984 about?
NCT07588984 is a clinical study titled "GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study". This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort s...
What is the current status of trial NCT07588984?
This trial is currently not yet recruiting. The enrollment target is 2,310 participants. The study started on 2026-04-30. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07588984?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Noom Weight (BEHAVIORAL), Free Tier (BEHAVIORAL), Education-only control (BEHAVIORAL).
Who is sponsoring clinical trial NCT07588984?
This trial is sponsored by Noom, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI